arrow
G

Gunjan L. Shah

Memorial Sloan Kettering Cancer Center
H指数:43
被引数:8,077

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A Pilot Study of Condensed Busulfan, Melphalan, and Fludarabine Myeloablative Conditioning in Ex Vivo CD34-Selected Allogeneic Hematopoietic Cell Transplantation

一项关于浓缩白消安、美法仑和氟达拉滨骨髓清除性预处理在体外CD34⁺选择的同种异基因造血细胞移植中的初步研究

2026-10-150
PRE
Dynamic risk stratification in smoldering multiple myeloma: Integrating evolving biomarkers with the 2/20/20 Model

动态风险分层在冒烟性多发性骨髓瘤中的应用:整合演变中的生物标志物与2/20/20模型

2026-09-240
OAAI
Stem cell autograft minimal residual disease negativity and survival outcomes for multiple myeloma autotransplant

自体干细胞移植后微小残留病阴性及多发性骨髓瘤自体移植的生存结局

2026-09-220
OAAI
Lesion-level PET/CT analysis to identify predictors of progression after BCMA CAR T-cell therapy in multiple myeloma

基于病灶水平的PET/CT分析以识别多发性骨髓瘤中BCMA CAR T细胞治疗后进展的预测因子

2026-08-190
OAAI
Impact of granulocyte colony-stimulating factors on cytokine release syndrome during bispecific antibody initiation in relapsed/refractory multiple myeloma

粒细胞集落刺激因子对双特异性抗体启动期间细胞因子释放综合征的影响:在复发/难治性多发性骨髓瘤中的作用

2026-08-070
OAAI
Robust CD4+ CAR T cell expansion is associated with non-ICANS neurotoxicities after ciltacabtagene autoleucel in patients with multiple myeloma

在多发性骨髓瘤患者中,强效CD4+ CAR T细胞扩增与非ICANS神经毒性的发生相关(cilta-cel治疗)

2026-07-290
PRE
Concurrent administration of BCMA and GPRC5D chimeric antigen receptor (CAR) T cells in advanced multiple myeloma

BCMA和GPRC5D嵌合抗原受体(CAR)T细胞在晚期多发性骨髓瘤中的联合给药

Blood
IF23.1
2026-07-080
PRE
Functionally high-risk disease is associated with poor outcomes after late-line CAR T-cell therapy for multiple myeloma

功能性高风险疾病与多发性骨髓瘤晚期CAR T细胞疗法后的不良预后相关

2026-04-120
OAAI
The Impact of Post-Transplant Interventions and Chronic GVHD on Survival in Myeloid Malignancies Harboring TP53 Alterations

TP53突变携带的髓系恶性肿瘤中,移植后干预和慢性移植物抗宿主病对生存的影响

2026-04-120
PRE
Impact of Novel Therapies on the Efficacy of Post-Transplantation Brentuximab Vedotin Maintenance in Hodgkin Lymphoma

新型疗法对移植后Brentuximab Vedotin维持治疗霍奇金淋巴瘤疗效的影响

2026-03-310
OAAI
IMS-IMWG 2025 consensus genomic staging predicts outcomes with daratumumab-based quadruplet regimens for NDMM

IMS-IMWG 2025年共识基因组分期可预测达雷木单抗为基础的四联方案对NDMM的疗效。

2026-02-190
OAAI
Two decades of single-institution data reveal rare longterm survivors of relapsed/refractory Burkitt lymphoma

二十年单机构数据揭示复发/难治性伯基特淋巴瘤的罕见长期生存者

2026-01-011
OA
PD-1-based combinations before autologous transplant are associated with improved outcomes in classical Hodgkin Lymphoma

基于PD-1的组合疗法在自体移植前与经典霍奇金淋巴瘤的改善预后相关。

Blood
IF23.1
2025-12-190
PRE
Outcomes of terminal complement blockade in adults with high-risk transplant-associated thrombotic microangiopathy: a comparative analysis

高危移植相关血栓性微血管病成人中终末补体阻滞的结局:一项比较分析

2025-11-280
PRE
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact

大B细胞淋巴瘤中CAR T细胞疗法后的晚期血液学毒性:发生率、危险因素及临床影响

2025-11-180
PRE
Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma

双特异性抗体治疗复发/难治性多发性骨髓瘤期间巨细胞病毒再激活

2025-11-010
OAAI
Patterns and safety of glucocorticosteroid use following CD19 CAR-T therapy for large B-cell lymphoma

CD19 CAR-T疗法后大B细胞淋巴瘤患者糖皮质激素使用模式与安全性

2025-11-010
OAAI